Literature DB >> 3113951

The effect of thrombin on the complex between factor VIII and von Willebrand factor.

R J Hamer, J A Koedam, N H Beeser-Visser, J J Sixma.   

Abstract

Purified human factor FVIII (FVIII; 6000-8000 U/mg) was radiolabeled and bound to immobilized von Willebrand factor (vWF). The complex was incubated with human thrombin. Thrombin induced a release of 65% of the radioactivity initially bound. Released FVIII fragments and fragments remaining bound during incubation with thrombin were analyzed using gel electrophoresis. This led to the following observations. Released fragments largely consisted of Mr-70000 and Mr-50000 fragments; Mr-90000 and Mr-80000 fragments were only found in the fractions remaining bound to vWF and decreased with time. In contrast to these digestion products of FVIII, the Mr-42000 heavy-chain fragment remained bound to vWF, comprising the larger part of the radioactivity after a 2-h incubation. No thrombin-induced cleavages were observed in vWF. Furthermore, vWF-coated wells preincubated with thrombin were still able to bind 125I-FVIII. These results implicate a new concept for the activation of vWF-bound FVIII. Activation is a multistep process in which several cleavages are necessary to produce and release a coagulant-active FVIII molecule (FVIIIa), which is probably an Mr-50000/70000 heterodimer. Inactivation of FVIIIa is likely to be the result of a nonproteolytic dissociation due to loss of the joining divalent cation(s).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3113951     DOI: 10.1111/j.1432-1033.1987.tb13331.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  11 in total

Review 1.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

2.  Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa.

Authors:  S W Pipe; R J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

3.  Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor.

Authors:  A M Aly; L W Hoyer
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

Review 4.  Haemophilia A and haemophilia B: molecular insights.

Authors:  D J Bowen
Journal:  Mol Pathol       Date:  2002-04

Review 5.  Viscoelasticity and Ultrastructure in Coagulation and Inflammation: Two Diverse Techniques, One Conclusion.

Authors:  Albe C Swanepoel; Vance G Nielsen; Etheresia Pretorius
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

Review 6.  Haemophilia A and haemophilia B: molecular insights.

Authors:  D J Bowen
Journal:  Mol Pathol       Date:  2002-02

Review 7.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

8.  Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain.

Authors:  Keiji Nogami; Midori Shima; John C Giddings; Masahiro Takeyama; Ichiro Tanaka; Akira Yoshioka
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

9.  Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor.

Authors:  J A Koedam; J C Meijers; J J Sixma; B N Bouma
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

10.  Blood Clotting Factor VIII: From Evolution to Therapy.

Authors:  N A Orlova; S V Kovnir; I I Vorobiev; A G Gabibov; A I Vorobiev
Journal:  Acta Naturae       Date:  2013-04       Impact factor: 1.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.